Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Human immunodeficiency virus 1 (HIV-1) integrase is a viral enzyme essential for the replication of HIV-1, the causative agent of AIDS. It catalyzes the integration of viral DNA into the host cell genome, a critical step that allows for persistent infection and efficient viral replication. This makes HIV-1 integrase a major target for antiretroviral drug development. HIV-1 integrase performs two main catalytic reactions during viral replication: 3'-Processing and Strand Transfer. By integrating its genome into host chromatin, HIV establishes lifelong infection, evades immune detection, and ensures stable expression and propagation within dividing cells. Integrase is targeted by several classes of antiretroviral drugs known as "integrase inhibitors" or "INSTIs" (e.g., raltegravir, elvitegravir, dolutegravir), which block strand transfer activity.
Inhibition of strand transfer activity
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human Immunodeficiency Virus 1 Integrase (None).